Belyntic has pioneered an innovative vaccine technology designed to trigger robust and enduring cellular immune responses via prime/boost vaccination. Our vaccine candidates harness self-adjuvant synthetic long peptides (SLPs), which integrate MHC class I and class II epitopes alongside essential functional units like enzymatic cleavage sites to ensure precise release of active components. The molecular architecture, notably the covalently linked adjuvant, confers SLPs with several advantageous properties, including stability enhancement, targeted immune cell interaction, and uptake. This unique structure that forms stable macromolecular particles enhances immunogenicity, establishing SLPs as an inherently efficient delivery system.